Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug

Veradermics, Inc

2026-Q1 EPS reported -$1.32

Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.
Positive Phase 2/3 topline results for VDPHL01 in male pattern hair loss; 12-month data H2 2026.
Enrollment completed in Study '304' (Phase 3, male PHL); topline data H2 2026. Study '306' (female PHL) enrolling.
Raised ~$766.8M gross from IPO and follow-on; cash $390.8M at Mar 31, 2026, expected to fund into 2030.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001827635-26-000016

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.